A Prospective, Randomized, Placebo Controlled, Double-Blind Study of Pelvic Electromagnetic Therapy for the Treatment of Chronic Pelvic Pain Syndrome With 1 Year of Followup

Rowe, Everton; Smith, Christopher P.; Laverick, L.; ELKABIR, JEREMY J.; Witherow, R. O’n.; Patel, Anand

doi:10.1097/01.ju.0000158445.68149.38

Cited by 54 publications

(42 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…9 Thus, initial investigations of clinical applications for extracorporeal magnetic innervation (ExMI) of the pelvic floor have focused on the treatment of stress urinary incontinence. However, Rowe et al 10 suggested that the use of electromagnetic therapy might be a promising non-invasive option for CP/CPPS. We hypothesized that depolarization can also occur in sensory afferent fibers and autonomic nerves that may regulate local blood flow and other factors.…”

Section: Introductionmentioning

confidence: 99%

More effects of extracorporeal magnetic innervation and terazosin therapy than terazosin therapy alone for non-inflammatory chronic pelvic pain syndrome: a pilot study

Paick

2006

Prostate Cancer Prostatic Dis

View full text Add to dashboard Cite

The objective of this study was to evaluate whether extracorporeal magnetic innervation (ExMI) combined with a-blocker therapy is more effective than a-blocker monotherapy for patients with non-inflammatory chronic prostatitis (CP)/chronic pelvic pain syndrome (CPPS), category IIIB. Patients were randomized to either terazosin monotherapy (group 1, n ¼ 21) or terazosin combined with ExMI therapy (group 2, n ¼ 19). Patients in group 2 had 12 treatment sessions of ExMI twice a week during 6 weeks. None of the patients experienced any side effects from treatment. The changes in each domain of the National Institutes of Health (NIH)-Chronic Prostatitis Symptom Index (CPSI) measured on week 6 were not significantly different between the groups. However, the difference (median, 25-75th percentiles) between the two groups in total NIH-CPSI scores was À4 (À11.5, À2) for group 1 and À12 (À17.3, À2.3) for group 2, respectively (P ¼ 0.047). At 6 weeks, 47.6% (10 of 21) of group 1 had a 425% decrease in total NIH-CPSI compared with 78.9% (15 of 19) of group 2 (P ¼ 0.041). Also, more patients in group 2 (78.9%) were rated as responders with a 6-point decrease in NIH-CPSI compared with group 1 (47.6%) (P ¼ 0.041). The early results suggest that ExMI combined with a-blocker therapy has better effect than a-blocker monotherapy for the treatment of CP/CPPS.

show abstract

Section: Introductionmentioning

confidence: 99%

More effects of extracorporeal magnetic innervation and terazosin therapy than terazosin therapy alone for non-inflammatory chronic pelvic pain syndrome: a pilot study

Paick

2006

Prostate Cancer Prostatic Dis

View full text Add to dashboard Cite

show abstract

“…Thus, initial investigations of clinical applications for ExMI of the pelvic floor have focused on treating stress urinary incontinence [12,13]. However, Rowe et al [17] suggested that electromagnetic therapy might be a promising noninvasive option for chronic pelvic pain. Previous studies reported that an interchanging magnetic field is effective for chronic pelvic pain and tissue trauma-induced pain in women [18,19].…”

Section: Discussionmentioning

confidence: 99%

“…Electromagnetic field therapy showed an analgesic effect on chronic pelvic pain in women [19]. Recently, promising results were reported for the use of electromagnetic treatment for chronic pelvic pain [17]. While the somatic pain is mainly transmitted by the Aβ fiber (myelinated fiber showing quick nerve-transmitting speed and low stimulation threshold value), the visceral pain responding to thermal stimulation is transmitted by the C fiber (unmyelinated fiber showing slow transmitting speed and transmitting the stimulation of the autonomic nervous system [20]).…”

Section: Discussionmentioning

confidence: 99%

Can Extracorporeal Magnetic Innervation Be a Treatment Modality for Primary Dysmenorrhea

Aydoğmuş

Keskin²,

Aydoğmuş

et al. 2014

Gynecol Obstet Invest

View full text Add to dashboard Cite

Background/Aims: To evaluate the efficacy of extracorporeal magnetic innervation (ExMI) as a treatment for primary dysmenorrhea compared with nonsteroidal anti-inflammatory drugs (NSAIDs) and combined oral contraceptives (COCs). Methods: The cases were randomized into three groups (NSAID = 51, ExMI = 53, COC = 54). ExMI was applied for a total of 10 sessions. Women in the NSAID group used an oral NSAID at the start of each menstruation. Women in the COC group were given combined pills. Of the treatment options, ExMI was applied for only a single period, whereas NSAID and COC use continued for 12 months. Results: At the first menstruation, visual analog scale (VAS) scores improved significantly in all groups (p < 0.001). NSAIDs and COCs continued to show efficacy over the entire study period (p < 0.05). However, in the ExMI group, VAS values increased from the first menstruation until 12 months. The VAS score at the 12th month was significantly higher in the ExMI group than in the other groups (p < 0.05), but markedly lower than the pretreatment value (49.9 ± 8.3 vs. 71.1 ± 10.1, p < 0.001). Conclusions: ExMI therapy might be a promising novel noninvasive option for primary dysmenorrhea. Efficacy began to decline after 3 months, but continued for 12 months.

show abstract

“…A rapidly changing electromagnetic field noninvasively applied to the perineum may result in neural excitation and pelvic floor muscle stimulation to a degree that breaks the cycle of tonic muscular spasm and neural hypersensitivity and inflammation, thereby regulating pelvic floor muscular activity [77]. In a study by Rowe et al [77], 21 patients with CP/CPPS were prospectively randomized to receive active electromagnetic or placebo therapy.…”

Section: Electromagnetic Therapymentioning

confidence: 99%

Minimally Invasive Therapies for Chronic Pelvic Pain Syndrome

2010

View full text Add to dashboard Cite

Chronic pelvic pain syndrome (CPPS) is a common problem among men and women worldwide. It is a symptoms-complex term for interstitial cystitis/painful bladder syndrome in women and chronic prostatitis/chronic pelvic pain syndrome in men. Patients often present with a combination of lower urinary tract symptoms with pelvic pain and sexual dysfunction. No gold standard exists for diagnosis or treatment of CPPS. The diagnosis is often challenging and is determined by elimination. Multiple treatment modalities exist, ranging from physical therapy to surgery. We discuss minimally invasive therapies for treatment of this complex of symptoms. Although data suggest reasonable efficacy of several medications, multimodal therapy remains the mainstay of treatment. We review the following minimally invasive therapeutic modalities: dietary modifications, physical therapy, mind-body therapies, medical therapy, intravesical therapies, trigger point injections, botulinum toxin injections to the pelvic floor, and neuromodulation. We report data supporting their use and efficacy and highlight the limitations of each.

show abstract

A Prospective, Randomized, Placebo Controlled, Double-Blind Study of Pelvic Electromagnetic Therapy for the Treatment of Chronic Pelvic Pain Syndrome With 1 Year of Followup

Abstract: The novel use of pelvic floor electromagnetic therapy may be a promising new noninvasive option for chronic pelvic pain syndrome in men.

Cited by 54 publications

References 15 publications

More effects of extracorporeal magnetic innervation and terazosin therapy than terazosin therapy alone for non-inflammatory chronic pelvic pain syndrome: a pilot study

More effects of extracorporeal magnetic innervation and terazosin therapy than terazosin therapy alone for non-inflammatory chronic pelvic pain syndrome: a pilot study

Can Extracorporeal Magnetic Innervation Be a Treatment Modality for Primary Dysmenorrhea

Minimally Invasive Therapies for Chronic Pelvic Pain Syndrome

Contact Info

Product

Resources

About